Jane Street Group LLC lessened its holdings in shares of Nuvation Bio Inc. (NYSE:NUVB - Free Report) by 71.7% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 84,039 shares of the company's stock after selling 213,290 shares during the quarter. Jane Street Group LLC's holdings in Nuvation Bio were worth $192,000 as of its most recent filing with the SEC.
Other hedge funds have also recently bought and sold shares of the company. FMR LLC raised its holdings in shares of Nuvation Bio by 1.4% during the 3rd quarter. FMR LLC now owns 29,238,871 shares of the company's stock valued at $66,957,000 after buying an additional 416,932 shares during the period. State Street Corp raised its stake in shares of Nuvation Bio by 4.8% during the third quarter. State Street Corp now owns 4,166,441 shares of the company's stock valued at $9,541,000 after purchasing an additional 191,031 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Nuvation Bio by 4.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,394,015 shares of the company's stock worth $3,192,000 after purchasing an additional 60,590 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Nuvation Bio by 415.2% in the second quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company's stock valued at $2,975,000 after purchasing an additional 820,669 shares during the period. Finally, Wexford Capital LP boosted its stake in shares of Nuvation Bio by 930.2% in the third quarter. Wexford Capital LP now owns 651,767 shares of the company's stock valued at $1,493,000 after purchasing an additional 588,500 shares during the period. Hedge funds and other institutional investors own 61.67% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on NUVB. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Nuvation Bio in a research report on Monday, January 6th. Wedbush restated an "outperform" rating and set a $5.00 price objective on shares of Nuvation Bio in a report on Monday, January 6th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 target price (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Nuvation Bio presently has a consensus rating of "Buy" and a consensus price target of $7.40.
Get Our Latest Analysis on NUVB
Nuvation Bio Stock Performance
Shares of Nuvation Bio stock traded down $0.12 during trading hours on Monday, reaching $2.66. The company's stock had a trading volume of 3,551,587 shares, compared to its average volume of 3,478,616. Nuvation Bio Inc. has a one year low of $1.43 and a one year high of $4.16. The company's 50 day simple moving average is $2.76 and its 200 day simple moving average is $2.82. The stock has a market cap of $895.27 million, a P/E ratio of -1.23 and a beta of 1.47.
Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The business had revenue of $0.73 million during the quarter. On average, sell-side analysts predict that Nuvation Bio Inc. will post -0.4 earnings per share for the current fiscal year.
About Nuvation Bio
(
Free Report)
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
Featured Articles
Before you consider Nuvation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.
While Nuvation Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
